The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Biology Consortium, 2017Development of Nanobodies as Novel Tools to Characterize LRRK2 as a Potential Drug Target for Parkinson's Disease
Study Rationale:
Several genes play a crucial role in Parkinson's disease (PD). The most common genetic cause of PD is mutations in the gene encoding LRRK2, a very large and complex protein with... -
Research Grant, 2017Gene Therapy to Restore Protein Imbalance in Parkinson's Disease
Study Rationale:
Parkinson's disease (PD) is characterized by impairment of motor control as a result from extensive neuron death. The primary mechanism responsible for the progressive neuronal loss in... -
Research Grant, 2017External Validation of Proteos Alpha-synuclein Pre-formed Fibrils
Study Rationale:
A reliable, characterized and validated model of synucleinopathies (disorders in which there is an excessive accumulation of the protein alpha-synuclein) would provide a critical tool... -
Research Grant, 2017Optimization of Dopamine Compounds for the Treatment of L-DOPA-induced Dyskinesias (LIDs)
Promising Outcomes of Original Grant:
In our original proposal, we identified two chemical scaffolds (protein support structures) as dopamine receptor 4 (D4R) antagonists (compounds that block the... -
Oligomeric & pS129 Assay LEAPS, 2017Exploring the Use of Alpha-synuclein Assays for Translational Biomarkers and Pharmaceutical Intervention Trials
Study Rationale:
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. The biggest roadblock facing the development of disease-modifying therapies is... -
Target Advancement Program, 2017Antibody Therapy to Block Alpha-Synuclein Spread and Toxicity
Study Rationale:
Parkinson's disease (PD) is characterized by the accumulation of misfolded pathologic alpha-synuclein. This toxic alpha-synuclein moves between neurons and causes progressive neuronal...
![Two female doctors talking in the lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/apply-for-grant-404-Large-Image-Callout-A-1.jpg?h=2a1ad497&itok=-_5jZ5iX)
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.